Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine
Authors:
Open Access
- 12 August 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 935362
Abstract
Long-term use of olanzapine, an antipsychotic drug, induces hypertriglyceridemia, resulting in a higher risk of cardiovascular disease. However, the effects and underlying mechanisms of short-term use of olanzapine on circulating triglyceride levels remain poorly understood. Here, the role of apolipoprotein A5 (apoA5), a regulator of triglyceride metabolism, was investigated in olanzapine-induced hypertriglyceridemia. Our multi-center clinical study recruited 36 schizophrenia patients who received short-term (8 weeks) of olanzapine. Besides, female C57BL/6J mice were treated with olanzapine (3 mg/kg/day versus 6 mg/kg/day) for 6 weeks. We demonstrated that short-term use of olanzapine increased plasma triglyceride and decreased plasma apoA5 levels in the patients and mice, with a negative correlation between the two factors. However, no obesity was observed in the patients and mice. Interestingly, olanzapine increased hepatic apoA5 protein in the mice, without significant changes in hepatic Apoa5 mRNA. Consistently, in vitro studies indicated that olanzapine increased medium triglyceride levels and decreased medium apoA5 levels in a dose-dependent manner in human HepG2 cells and primary mouse hepatocytes. Whereas the olanzapine treatment increased hepatic apoA5 protein in vitro, without effects on hepatic APOA5 mRNA. Of note, olanzapine increased the co-localization between apoA5 protein and accumulated lipid droplets in hepatocytes, as opposed to at the hepatocellular plasma membrane, in mouse liver as demonstrated by fluorescence staining. Therefore, our study indicated that short-term use of olanzapine induced hypertriglyceridemia due to defects of sorting and secretion of hepatic apoA5.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81974281)
- Natural Science Foundation of Hunan Province (2020JJ2052)
This publication has 53 references indexed in Scilit:
- Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitroJournal of Lipid Research, 2013
- Apolipoprotein A-V dependent modulation of plasma triacylglycerol: A puzzlementBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretionJournal of Lipid Research, 2011
- Increasing off‐label use of antipsychotic medications in the United States, 1995–2008Pharmacoepidemiology and Drug Safety, 2011
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout miceBiochemical and Biophysical Research Communications, 2010
- Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindoleInternational Journal of Obesity, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐αBritish Journal of Pharmacology, 2009
- Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cellsPharmacological Research, 2007